Dr Peter FitzGerald: “Nothing will ever be the same again.”

Home - Blog Articles - Page 3

Dr Peter FitzGerald: “Nothing will ever be the same again.”

Dr Peter FitzGerald: Nothing will ever be the same again.

An Interview with Ulster Business Editor John Mulgrew in The Belfast Telegraph, in which Dr FitzGerald speaks to John about developing and helping roll out millions of tests for Covid-19, a forever changed society, the high likelihood of a similar pandemic returning and when a vaccine for the virus could be found.

Dr Peter FitzGerald’s expertise and opinion has probably never been taken as seriously as it has in the last few months.

“Nothing will be the same again,” he tells Ulster Business. And, of course, he’s right.

His firm Randox – based in Antrim – has been on the front line of testing for Covid-19 right across the UK and beyond. And as a result, he’s hired hundreds of new staff and built a £30m testing lab to deal with additional deluge of work resulting from a global pandemic unlike anyone here has ever seen.

“I think there is a reasonable chance there will be more pandemics, with globalisation and increased population,” he told Ulster Business. “I have no idea how much it will come back again in second wave.

“We know we have the capacity as a company to respond, and respond well. I suspect the country is going to be better prepared… it’s hard to predict.”

The medical testing giant’s first involvement with the current coronavirus strain began back in January, before it became an increasingly concerning dinner conversation in homes across Northern Ireland.

“In late January, research called and were looking at doing a test,” Peter said. “We downloaded the genetic sequence of the virus and spent the next two weeks developing a test. We can do it very quickly, as we already had coronaviruses on chip.

“It was sent to Public Health England, which took a while to prove it. We then got a contract to test for the NHS… we were doing what we thought was for the national good.”

The initial deal didn’t include all of the UK, but Randox is now also testing Northern Ireland.

“We do the testing and we have different analysers that do the testing as well, which we sell to labs across the world.”

The virus has led to a new complete lab being built (in which Peter is pictured in) to deal with the additional testing. “We decided to accelerate the manufacturing in our Randox Science Park in Antrim,” he says.

As a result, it has hired around 200 staff in the space of six to eight weeks to deal with the surge.

“Because we had closely related strains of the virus, it was wasn’t so difficult to modify our tests to allow for slightly different variations… once we got the contract we soon realised that we didn’t have enough lab space to deal with the ramp up.

“We then decided to be 33,000 sq ft of new lab space, and it was needed in three weeks. We got that done – work was 24 hours a day, and seven days a week. It’s now operating well. That has been very important in the process.”

Randox had a workforce of around 1,450 worldwide before the coronavirus crisis began, but has since taken on around 280 additional staff for a range of roles, partly in ramping up demand for the additional testing.

“A lot were being taken on a temporary basis but many will be permanent. We are not sure of the final numbers, but well over 100.” Those roles include scientists, manufacturers, and engineers.

“Nothing will be the same again,” Peter says. “What it has done is heightened the importance of testing. People sometimes don’t know what we do here at Randox… but people now realise.

“In the end, it’s a good thing. We are advocates of testing. It identities disease before symptoms occur and can save lives in many occasions. It saves lives and saves costs. It fits in with what we have been trying to do for years… as far as we are concerned, it’s the silver lining.

“We have customers worldwide and other products kept going. We moved around 100 scientists into Covid-related things and then they have gone back to normal jobs as we bring in new people.

“Some of our R&D projects have changed, new systems and new analysers allow for efficient and accurate testing.”

Peter says that just a small element of the business has seen a decrease amid the crisis, while other areas around Covid-19 have grown. “Only a small element of core business decreased. But our Covid and other genetic products have increased… overall sales will be up and by end of year normal business up as well.”

As a result of the latest expansion and growth across the business, generally speaking, Peter says the workforce looks set to climb to 1,650, with around 500-600 based at its main headquarters, just outside Antrim.

Peter’s also keen to reiterate the importance of Northern Ireland and its people to Randox. “This is our home base. It’s where we do our primary R&D and manufacturing. We also have a facility in Donegal.”

And, could all of this happen again soon, with a further outbreak or a similarly devastating strain or pandemic?

“(We are) more prepared and our technology is getting more accepted through bio chips. Early detection is a very important next stage. You don’t want people who have a cough or fever to think they have Covid all the time. That is where testing comes in and that differentiates.”

Peter says the next stop forward in a bid to address similar future incidents it also understanding how our immune systems work – better.
“The other major step forward in many ways is understanding the immune system better. How to better respond to infection. This will be very important.

“Some people are susceptible, and this could be genetic. (It’s about) working on certain genes in those who may have a bad attack. It will prepare humans better, the body’s defence, dealing with it as well.

“I have a deficiency in a particular gene which means I’m more susceptible to respiratory (conditions) but the spin-off of the gene means I’m less susceptible to certain cancers. This is the issue – it is so complex. One could be a strength and one moment, a weakness.”

And as for the formulation of a proven vaccine, Peter says: “I would say it would be well into next year.”

    For further information please email randoxpr@randox.com

    Photo Credit Elaine Hill

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our Randox Products and Services

    REAGENTS

    RX SERIES

    ACUSERA

    BIOCHIP


    Acute Kidney Injury

    Acute Kidney Injury

    Rapid Renal Injury Detection

    Multiplex Detection of Acute Kidney Injury from a Single Sample

    • null
      Simultaneous and quantitative detection of multiple kidney function markers from a single patient sample for complete patient profiling
    • null
      Identify early stage renal impairment and ensure earlier intervention. Widely used in drug-related renal clinical trials
    • null
      Unique combination of analytes ensures better sensitivity and accuracy compared to traditional serum creatinine measurement
    • null
      The Randox AKI array measures four qualified FDA urine markers from one sample
    • null
      Multiplex testing better captures reduced renal function, as each biomarker reflects different mechanisms that result in similar injury outputs
    • null
      Utilising patented Biochip Technology, the Randox AKI array is currently available on the Evidence Investigator

    Acute kidney injury (AKI) is currently diagnosed using serum creatinine as recommended by the KDIGO guidelines.  Serum creatinine however, has poor sensitivity and specificity for AKI lagging behind both renal injury and recovery.  There is an immediate need for  more sensitive biomarkers to enables earlier identification of AKI, monitor drug toxicity and identify  patients at an increased risk of CKD, end-stage renal disease or long-term kidney dialysis.

    The National Institute for Health and Care Excellence (NICE) has highlighted that is important that patients are assessed for AKI on admission to hospital or transfer, monitored for AKI throughout their stay and AKI is managed appropriately if it develops.

    Utilising patented Biochip Technology, the Randox Acute Kidney Injury (AKI) array simultaneously tests for four novel biomarkers delivering early diagnosis and monitoring of treatment efficacy  It may also help you conduct safer and faster clinical trials.

    Biochip

    Randox Acute Kidney Injury (AKI) Array (4-plex)

    • Lipocalin (NGAL)
    • Cystatin C
    • Clusterin
    • Kidney Injury Molecule-1 (KIM-1)

    This marker is highly upregulated in kidney tubule cells following nephrotoxic injury severe enough to result in acute renal failure, acute tubular necrosis or acute tubulo-interstitial nephropathy.

    Due to its small size and basic pH, Cystatin C is freely filtered by the glomerulus. It is then reabsorbed by tubular epithelial cells and subsequently metabolized. Accumulation of Cystatin C in urine is specific for tubular kidney damage and suggests reduced reabsorption at the proximal tubules as a result of toxicant-induced kidney injury.

    Expression of Clusterin is upregulated following a variety of renal injuries and is detectable in urine following acute kidney injury induced by administration of nephrotoxic agents. This occurs before the profound renal transformations that give rise to changes in creatinine and BUN.

    KIM-1 is a 30kDa type 1 transmembrane glycoprotein found on actvated CD4+ T cells. It is undetectable in healthy kidney tissue but is expressed at very high levels in proximal tubule epithelial cells in the kidney after toxic injury.

    The Evidence Investigator

    Meet the Evidence Investigator

    The Randox AKI array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyser.

    The AKI array would improve patient risk stratification whilst monitoring the effectiveness of treatments & drug toxicity by simultaneously and quantitatively detecting multiple serum biomarkers of kidney damage-related analytes from a single sample.

    Evidence Investigator

    Want to know more?

    Contact us or visit our Investigator Webpage


    Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report

    News       About Us        Randox Toxicology

    Chicago’s Rising Fentanyl Problem: A Randox Toxicology Report

    Abuse of opioids, and in particular, fentanyl, has been on the rise in the United States in recent years. The number of patients being prescribed painkillers has almost quadrupled since the 90s from 76 million to 289 million in 2016. It has been described as a uniquely American problem, where pain relief prescriptions are about 40% higher than other developed countries.

    Inevitably due to the high addiction rate of opioids, this has unfortunately led to increasing overdose deaths. In 2017 alone over 70,000 people died from drug overdoses in the USA with opioids being involved in 67.8% of cases.

    Chicago Illinois is no exception to this crisis. The National Institute of Drug Abuse found that Illinois has a rate of 17.2 deaths per 100,000 people from opioid overdoses, compared to the national average of 14.6. It is not only prescription painkillers that are adding to the opioid addiction crisis in Chicago, but substances such as fentanyl that is illegally sold on the street.

    Fentanyl is a cheaper, synthetic opioid which can be 50 times more potent than heroin and 100 times more potent than morphine. It is commonly added to heroin to increase strength and cut costs. Many users believe they are purchasing heroin when in fact it can be mostly fentanyl, resulting in rising overdose deaths. The DEA’s Chicago lab have stated that the drug is making up a more of their workload than ever and becoming a regular drug they see.

    Randox Toxicology

    Randox Toxicology are world leaders in drug testing solutions with the capability of detecting over 500 drug and drug metabolites using our innovative Biochip Array Technology – the most comprehensive on the drug testing market. Using our revolutionary patented Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyzer that enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs of abuse from a single sample.

    Designed to work across a variety of matrices including; whole blood, urine, and oral fluid our patented multi-analyte testing platform provides a complete and highly accurate toxicology profile in 17-20 minutes. Most impressively the MultiSTAT has been designed to be fully operated from sample input to results output by someone with absolutely no laboratory experience and in any environment.

    To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

    Randox Toxicology Products and Services

    BIOCHIP

    EVIDENCE

    ELISA

    MATRICES

    Want to know more about Randox?

    Contact us or visit our homepage to view more.


    Alcohol consumption during the COVID-19 pandemic

    09 July 2020

    Alcohol consumption during the COVID-19 pandemic

     

    Alcohol consumption during the COVID-19 pandemic

    On 31 December 2019, the Wuhan Municipal Health Commission in Wuhan City, Hubei province, China, reported a cluster of 27 pneumonia cases (including seven severe cases) of unknown aetiology, with a common reported link to Wuhan’s Huanan Seafood Wholesale Market, a wholesale fish and live animal market. On 23 January 2020, Wuhan City was locked down – with all travel in and out of Wuhan prohibited –and movement inside the city was restricted.

    By March, the World Health Organisation (WHO) declared COVID-19 a global pandemic, with more than 150 countries worldwide being affected. Many countries, including the UK; imposed stringent public health measures that included the closure of businesses & strict social distancing guidelines.

    Due to the enforced lockdown, many within the UK workforce had to make alternative working arrangements, with working from home becoming the new norm. With the closure of businesses and the hospitality sector including bars and restaurants, it meant people seeking alternative means to purchase and consume alcohol.

    Before the pandemic, alcohol was attributed to being a financial burden to the UK health system and wider economy. The British Medical Journal estimated that alcohol costs the NHS more than £3.5 billion and the wider economy at least £21bn each year.

    The organisation Alcohol Change UK commissioned new research to look at whether people’s drinking habits changed during the COVID-19 lockdown. Over 2,000 people completed the survey, with results weighted to ensure they were representative of the UK population.

    The key takeaway from the report is people are consuming alcohol differently because of the lockdown. Around one in five drinkers (21%) told us that they have been drinking more frequently since the lockdown. This suggests that around 8.6 million UK adults are drinking more frequently under lockdown.

    Furthermore, while almost half of drinkers said they were drinking about the same amount on a typical drinking day, 15% said they have been drinking more per session since lockdown.

    The Global Drug Survey produced a special report for COVID-19 with more than 80,000 participants. The report stated that 44% of those who participated said the frequency of alcohol use increased. Reasons for this included ‘having more time to drink and feeling bored more often.’ However, 25.5% reported having decreased their use of alcohol during COVID-19.

    As restrictions begin to ease and more people return to work, it is important to highlight the impact of COVI-19 on the workforce. People’s way of life has changed dramatically, with this change comes different ways of consuming alcohol. It is important to note that the figures above are a proportionate representation based on those who took part, but valuable insights can be gained when looking at alcohol use. For employers who have staff returning to work, their safety is of paramount importance. This will include effectively managing substance misuse, should it be an issue in the workplace.

    Effects of Alcohol

    Alcohol’s impact on your body starts from the moment you take your first sip. While an occasional glass of wine or beer isn’t a cause for concern, the cumulative effects of drinking wine, beer, or spirits can take its toll.

    Consumption of alcohol can impact various parts of the body. Effects can range from weakening of the immune and digestive system, to inflammation and sugar level issues.

    Our ‘Effects Of’ Series provides educational posters that can be displayed in workplaces to highlight the dangers of alcohol. Click here for more information.

    About Randox Testing Services

    Randox Testing Services are a specialist in the workplace drug & alcohol testing sector. We provide a wide range of testing for companies who want to reduce the impact of substance misuse in the workplace. With a range of service options and expert staff on hand to provide help and training, our services will help to eradicate the impact of drugs and alcohol.

    Throughout the COVID-19 pandemic, RTS have continued to provide drug & alcohol testing services. At all times, we have ensured our staff are equipped to provide sensible advice and flexible solutions to drug & alcohol testing.

    We have provided each Collection Officer with full PPE to ensure they meet requirements for personal and professional safety. Full social distancing guidelines are followed at all times when possible whilst conducting testing. We will continue to advise and navigate companies through this period as more businesses return and testing is required.

    If you have any questions regarding drug & alcohol testing, contact us today.

    Web: www.randoxtestingservices.com

    Email: testingservices@randox.com

    Phone: +44 (0) 28 9445 1011

     

     

    Want to know more?

    Contact us or visit our website to read more.


    RX modena and Randox Reagents used in COVID-19 hospital in India

    News       RX modena       COVID-19

     

     

    18 June 2020

    RX modena and Randox Reagents used in COVID-19 hospital in India

    Randox Laboratories has installed an RX modena into a COVID-19 hospital in India; the Netaji Subhash Chandra Bose Medical College in Madhya Pradesh state.

    The installation, which marks the first RX modena to be used in an Indian Government Medical College, replaces existing instrumentation in the Medical College laboratory, an initiative which was driven by College Dean Dr. Pradeep Kumar Kasar and Head of Department Dr. Ashok Kumar Sahu.

    The RX modena will cater for an additional 38 samples compared to the previous instrumentation, and is running a range of biochemistry tests that play a pivotal role in COVID-19 patient management, including C-Reactive Protein (CRP), Ferritin, and Lactate Dehydrogenase (LDH).

    Dr. Ashok Kumar Sahu, Head of Biochemistry at Netaji Subhash Chandra Bose Medical College, commented;

    “We are very pleased with the performance of the RX modena, and in particular with its wide menu of tests that can be utilized for COVID-19 patient management. Its high throughput and versatility have been a great support for the clinicians working in our COVID-19 hospital, in determining risk stratification, disease progression, and response to treatment.”

    The RX modena is a high volume, floor standing, fully automated clinical chemistry analyser with a world leading test menu which covers specific proteins, lipids, therapeutic drugs, antioxidants, diabetes and veterinary testing. The versatile analyser offers advanced methodologies with excellent correlation to the gold standard, and excellent reagent CV ranges.

    Shail Dholabhai, Randox India Sales Manager, commented;

     “We are delighted that the team at Netaji Subhash Chandra Bose Medical College have chosen the RX modena to fulfil the testing requirements of this COVID-19 hospital. Offering an unrivalled test menu of routine and specialized chemistries, the RX modena provides laboratories with the superior precision, reliability and accuracy that the Randox RX series is renowned for.

    “Capable of performing a total of 1200 tests per hour including ISE, the RX modena presents a new class of efficiency which will result in faster and more accurate diagnoses, and ultimately, lead to better patient outcomes.”

    Benefits of the RX modena

    • Capable of performing 800 photometric and a total of 1200 tests per hour including ISE.
    • World-leading extensive test menu covering routine chemistries, specific proteins, lipids, antioxidants, cardiac, diabetes and veterinary testing, offering cost savings through consolidation of routine and novel tests on a single platform.
    • Economic platform with low water consumption of less than 20 litres per hour saving on consumable costs. The RX modena also requires less than 5 minutes minimal maintenance.
    • Interactive touch-screen technology with integrated barcode readers for reagent and sample identification. Increased functionality with 13 wavelengths generated via diffraction grating (340-800nm) ensuring a multitude of chemistries are possible on one system.
    • Easy-to-use advanced Microsoft 10 software with a built-in Inventory Management System calculating the number of tests remaining, providing alerts of shortages and expired reagents and calibrators. The RX modena also features automatic test re-run function and sample dilution.
    • Dedicated reagent and sample pipettes to minimise the risk of errors and contamination. The RX modena also features a continuous loading hatch to allow for samples to be analysed quickly and easily during a run.
    • Advanced QC capabilities with daily, monthly and batch QC with data archiving, Levey-Jennings charts and automatic QC and calibration. There are also 7 different calibration options available.

    For further information about the RX modena click here. 

    For information about laboratory tools for COVID-19 patient management please click here.

    For other enquiries please contact marketing@randox.com

     

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our Randox Products and Services

    REAGENTS

    RX SERIES

    ACUSERA

    BIOCHIP


    Staff Profiles

    We Are Randox

    • Staff Profiles

    COVID-19 Testing: PCR (Diagnostic) vs Antibody

    News       About Us       Randox Health

     

    18 June 2020

    COVID-19 Testing: PCR (Diagnostic) vs Antibody

    The advice from the World Health Organisation in relation to the COVID-19 pandemic has been simple; Test. Test. Test.

    But what are the different types of COVID-19 tests and what are they used for?

     

    Diagnostic (PCR) Testing

    This type of testing detects SARS-CoV-2 (the virus that causes COVID-19) within the body and will tell you if you currently have COVID-19. PCR tests cannot tell you if you have had past infection.

    Sample collection for a PCR test can vary, though it is usually in the form of a swab, which will gather an individual’s nasopharyngeal (nose and throat) secretions.

    PCR tests for COVID-19 all use methods that detect a specific part of the viral genome – for example Viral RNA or Antigen.  

    A sample is prepared by extracting the chosen section of the genome, and then PCR (Polyamerase Chain Reaction) techniques are used to amplify (replicate) the genome section, ready for detection.

    Viral RNA Tests

    This type of test detects the RNA (Ribonucleic acid) contained within the SARS-CoV-2 virus.

    It is this type of test, for RNA, that is recommended by The World Health Organisation for COVID-19 diagnosis.

    Antigen Tests

    Antigens are molecular structures on the surface of viruses that are recognized by the immune system and are capable of triggering an immune response.

    Antigen tests detect the presence of the SARS-CoV-2 virus by looking for the antigen on the surface of the virus.

    Randox COVID-19 Test

    The Randox COVID-19 test, as recommended by the World Health Organisation, detects the RNA contained within the SARS-CoV-2 virus.

    After sample extraction and amplification, the virus is detected on our patented Randox Biochip Technology platform.

    The Randox Biochip, which can run multiple tests simultaneously, performs two tests for COVID-19 – one specific and one confirmatory – as recommended by the WHO. This delivers extra assurance of the correct diagnosis and avoids the need to repeat the test.

     

    Antibody (Serology) Tests

    Antibody (also known as serology) tests, are usually performed on a patient blood sample, and look for antibodies (a type of protein) that may have been developed by the patient’s immune system to fight off disease.

    If present, antibodies may provide a degree of immunity for the patient against COVID-19 in the future.

    However, there is still much unknown about the body’s antibody response to COVID-19, including;

    • Whether all patients who have been infected with SARS-CoV-2 will generate antibodies (recent studies and news reports indicate that this isn’t the case. Click here for an example.)
    • Whether those who have had more severe symptoms as a result of COVID-19 will produce more antibodies than those who had mild symptoms, or were asymptomatic.
    • If antibodies from other coronaviruses previously experienced by the patient may be enough to fight off the virus, therefore eliminating the need for COVID-19 specific antibodies.
    • How long any COVID-19 specific antibody response will last for.
    • How much future immunity is provided by COVID-19 antibodies. Will it prevent the patient from being infected, or will future infection just be less severe?

    If antibodies for the SARS-CoV-2 virus are present this can give an indication that the patient has been previously infected with COVID-19. Antibody tests do not confirm the real-time presence of the virus in your system.

    For example, a negative antibody result does not necessarily mean the body has not been exposed to the SARS-CoV-2 virus. It could in fact, be currently infected, but has not yet generated antibodies. A diagnostic test will confirm current presence of the virus.

     

    Therefore, it is recommended that antibody tests are used in tandem with a diagnostic test to determine a complete overview of the patient’s COVID-19 status.

    Randox Health currently offers both diagnostic testing and antibody testing for SARS-CoV-2 (COVID-19).

    A combination of diagnostic and antibody testing is available for individual purchase, or as part of our ‘Back to Business’ COVID-19 testing service, for staff screening.

    Visit Randox Health to find out more.

    Want to know more about Randox?

    Contact us or visit our homepage to view more.

    Our Randox Products and Services

    REAGENTS

    RX SERIES

    ACUSERA

    BIOCHIP


    Why Choose Randox Reagents?

    Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have the largest test menu of over 100 assays, covering over 100 disease markers including specific proteins, lipids, therapeutic drug monitoring, drugs of abuse, antioxidants, coagulation, diabetes and veterinary testing.

    Some of the key benefits of Randox Reagents include:

    Reduced costs

    Randox reagents can help create cost-savings for laboratories through excellent reagent stability; by eliminating the need for costly re-runs through the excellent quality of products. We also offer a range of kit sizes including smaller kit sizes for niche tests to reduce waste.

    Reduce the risk of errors and have confidence in patient results

    Our traceability of material and extremely tight manufacturing tolerances ensure uniformity across reagent batches reducing lot-to-lot variability. In addition, our assays are validated against gold-standard methods, giving you the confidence that you are sending out the correct patient results.

    Reduced labour

    Reduce your time spent on running tests through liquid ready-to-use reagents, automated methods (compared to the traditional laborious ELISA methods used for some tests such as cystatin C or adiponectin) as well as our easy-fit options.

    Expand your routine testing

    With speciality assays for 195 of the most common clinical chemistry analysers; assays which usually require dedicated equipment, or was previously only available as an ELISA, can now be run on automated biochemistry analysers, allowing your laboratory to expand its routine test menu. For example, cystatin C, adiponectin, TxBCardio™ and many more.

    Bring testing in-house

    With smaller kit sizes and excellent reagent stability (most are stable for 28 days on-board the analyser), you don’t have to worry about reagent wastage, allowing testing to be brought in-house rather than sent to external laboratories.

    Expand your test menu without expanding your lab

    There is no need to buy any extra equipment in order to expand your test menu. Our reagents can be programmed onto the majority of the most common biochemistry analysers. At present, we have hundreds of applications available.

     

    Visit our Reagents Resource Hub and Download our reagents brochure for information on the full range of biochemistry reagents.

    Randox reagents are available for a wide range of clinical chemistry analysers. For more information, please contact reagents@randox.com


    Drug Use in Australia: A Randox Toxicology Report

    News       About Us        Randox Toxicology

    19 March 2020

     

     

     

    Drug Use in Australia

     

     

    Drug Use in Australia: A Randox Toxicology Report

    Approximately 43% of all Australians aged 14 years and over have admitted to using an illicit drug on at least one occasion throughout their life.

    Additionally, nearly 16% of Australians have confessed to using an illicit drug at least once in the last year.

    Cannabis is the most frequent drug used among the Australian people with an estimate of 35% lifetime use. The closest to this is MDMA which has an estimate of around 11% lifetime use.

    A reason towards the high cannabis use may be due to the Australian Capital Territory legalizing the recreational possession and cultivation of marijuana in September 2019. This now allows any residents of the capital territory over the age of 18 to possess up to 50 grams of dried marijuana and grow two plants per person or four per household at a time. The supply of the drug to other people however still remains an illegal act.

    It is estimated that approximately 60 per cent of those who use illicit drugs are also daily smokers and/or consume alcohol at a level that is considered to be of risk to their everyday health. Another noticeable finding among drug users in Australia is that the majority of methamphetamine, cocaine or ecstasy users are also users of other illicit drugs.

    Using our revolutionary Biochip Array Technology, the Evidence MultiSTAT is a fully automated benchtop analyser that enables onsite, simultaneous testing for up to 21 classical, synthetic or prescription drugs from a single sample in under 20 minutes.

    To find out more about our Biochip Array Technology and our Evidence Series range of analysers, visit www.randoxtoxicology.com or email info@randoxtoxicology.com

    Randox Toxicology Products and Services

    BIOCHIP

    EVIDENCE

    ELISA

    MATRICES

    Want to know more about Randox?

    Contact us or visit our homepage to view more.


    RTS Blog | Wales introduce minimum alcohol pricing

    12 March 2020

    Wales introduce minimum alcohol pricing

     

    RTS Blog | Wales introduce minimum alcohol pricing

    From 2nd March, there was a change in the way alcohol is sold in Wales, with the introduction of minimum unit pricing (MUP).

    Retailers and any outlets serving alcohol must charge at least 50p a unit, meaning a typical bottle of wine costs no less than £4.69. Welsh Health Minister Vaughan Gething said it would tackle “harmful and damaging” drinking of cheap, strong alcohol.

    A recent report found that alcohol sales in Scotland had dropped after a similar system was implemented in May 2018. The Public Health Minimum Price for Alcohol Wales Act 2018 forces retailers to use a formula for working out minimum pricing.

    What is a unit of alcohol?

    • A unit is 10ml of pure alcohol
    • This is equivalent to about half a pint of lower or standard-strength beer or cider
    • A single 25ml shot of sprits is about one unit
    • A small 125ml glass of wine contains about 1.5 units

    Source: NHS Direct Wales

    What is minimum unit pricing?

    Minimum unit pricing (MUP) is a method in setting a baseline price below which no one can sell an alcoholic drink. The price is based on how much alcohol is in each drink. The minimum price that’s being set in Wales is 50p per unit of alcohol. Whether the drink is beer, cider, wine, spirits or any other kind of alcoholic drink; its minimum price will depend on how much alcohol it contains. For example:

    • A standard-strength pint of beer or cider contains around 2.5 units of alcohol, so it can’t be sold in Wales for less than £1.25 (2.5 x 50p)
    • A bottle of wine has about 10 units of alcohol in it, so the minimum price for it is around £5 (10 x 50p)
    • A bottle of whisky or vodka contains around 26 units, and so cannot be sold for less than £13 (26 x 50p)

    Why has it been introduced?

    Official figures show about 500 people die in Wales each year from alcohol-related causes, with 60,000 hospital admissions related to alcohol consumption, adding up to an estimated £159m cost to the Welsh NHS r.

    Dr Sarah Aitken, director of public health for Aneurin Bevan University Health Board, said the organisation had been supportive of the law change since it was first mooted.

    “We see the effects of excessive alcohol consumption on people’s health every day,” she said.

     About Randox Testing Services

    Randox Testing Services are a specialist in the workplace drug & alcohol testing industry. We provide testing solutions for companies who want to reduce the impact of substance misuse in their workplace. With a range of service options and expert staff on hand to provide help and training to staff, our services will help to eradicate the impacts of drugs and alcohol.

    To find out more about our range of products and how our service packages can help your company, contact us today.

    Email – testingservices@randox.com

    Phone – +44 (0) 28 9445 1011

     

    Want to know more?

    Contact us or visit our website to read more.


    Request a meeting
    ×
    Make an Enquiry - RX series
    ×
    Make an Enquiry - Reagents
    ×
    Kit Insert Request - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Kit Insert Request - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Reagents
    ×
    Make an Enquiry - Quality Control
    ×
    Make an Enquiry - RIQAS
    ×
    Make an Enquiry - RIQAS
    ×
    Make an Enquiry - Quality Control
    ×
    Make an Enquiry
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Biochip
    • This field is for validation purposes and should be left unchanged.
    ×
    Make an Enquiry - Molecular
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    • This field is for validation purposes and should be left unchanged.
    ×
    Make an Enquiry - Future Diagnostics
    ×
    Make an Enquiry - RX series (Product)
    ×
    Make an Enquiry - Quality Control
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - RIQAS
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Por favor, introduzca sus datos para ver nuestro último seminario